Phase 4
N=44
Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
Retinal Degenerations
Bottom Line
View on ClinicalTrials.gov: NCT00716586 ↗Enrolled (actual)
44
Serious AEs
0.0%
Results posted
Oct 2021
Primary outcome: Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- 2% dorzolamide (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Illinois at Chicago
- Primary completion
- Aug 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) |
36 | — |
| PRIMARY Number of Participants With Improvement in Macular Fluid as Measured Subjectively by Optical Coherence Tomography (OCT) |
36 | — |
| SECONDARY Number of Participants With Improvement of Seven Letters or More Read on a Visual Chart |
20 | — |
Summary
A small percentage of patients with retinal degeneration accumulate fluid in the center of their retina.
Previous studies using an oral form of treatment has been successful in decreasing this fluid which improves vision.
This study will test the use of a topically applied form of this treatment to the eye to reduce the amount of fluid and improve or preserve vision.
Eligibility Criteria
Inclusion Criteria
- Presence of cystic macular fluid on OCT testing
Exclusion Criteria
- Allergic reaction to sulpha containing compounds
- Intolerance to dorzolamide (Trusopt)
Data sourced from ClinicalTrials.gov (NCT00716586). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.